Sonrotoclax (BGB-11417; Beqalzi) is a next-generation, highly selective B-cell lymphoma 2 (BCL-2) inhibitor that recently received accelerated approval from the U.S. Food and Drug Administration (FDA) on May 13, 2026, for the treatment of adults with relapsed or refractory mantle cell lymphoma (R/R MCL) after at least two prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor. Approval was based on results from the phase I/II BGB-11417-201 study, which demonstrated clinically meaningful activity with a manageable safety profile in a heavily pretreated population.

FDA accelerated approval establishes sonrotoclax as a new targeted option for patients with BTK inhibitor–pretreated mantle cell lymphoma.

Clinical Takeaway

Sonrotoclax has demonstrated single-agent activity in relapsed or refractory mantle cell lymphoma, including in patients previously treated with BTK inhibitors, and is now FDA-approved under the accelerated approval pathway. As a selective oral BCL-2 inhibitor, it offers a targeted mechanism with a manageable safety profile. Approval was based on overall response rate and duration of response, and continued clinical benefit remains subject to confirmatory trials to verify clinical benefit.

Drug Profile & Mechanism

  • Agent: sonrotoclax (BGB-11417; Beqalzi)
  • Class: small-molecule BCL-2 inhibitor
  • Mechanism of action: Selectively inhibits the anti-apoptotic protein BCL-2, restoring mitochondrial apoptosis in malignant B cells while minimizing off-target BCL-xL inhibition
  • Route of administration: oral
  • Dosing Schedule: Once-daily oral administration with an initial 4-week ramp-up phase, followed by 320 mg once daily until disease progression or unacceptable toxicity
  • Target population: Adults with R/R MCL after ≥2 prior lines of therapy, including a BTK inhibitor

BGB-11417-201 Study Design (NCT05471843)

  • Study Type: Phase I/II, open-label, multicenter, single-arm
  • Population:
    • R/R MCL (n = 103)
    • Prior anti-CD20–based therapy and BTK inhibitor exposure
    • Heavily pretreated
  • Comparator: n/a (single-arm study)
  • Treatment Regimen: monotherapy administered orally once daily following dose-escalation/ramp-up
  • Follow Up Duration:
    • n/a; follow-up immature at time of reporting
  • Primary and Key Secondary Assessments:
    • Primary: Safety and tolerability; determination of recommended phase II dose (RP2D)
    • Secondary: overall response rate (ORR), duration of response (DoR), progression-free survival (PFS), pharmacokinetics
  • Estimated study completion: n/a, ongoing at time of data release
  • Key Endpoints:
    • Primary: Safety, dose limiting toxicities, RP2D
    • Secondary: ORR, complete response (CR) rate, DoR, PFS

Efficacy Outcomes

  • Primary Endpoint Results:
    • n/a (safety focused in phase I)
  • Secondary Endpoint Results:
    • Approval was based on objective response and durability in a heavily pretreated population.
    • Overall response rate (ORR) was 52% (95% CI: 42–62), with a median time to response of 1.9 months.
  • Duration of Response (DoR):
    • Median DoR was 15.8 months (95% CI: 7.4, not estimable), with a median follow-up of 11.9 months.
  • Overall Survival (OS): n/a
  • Hazard ratio for death: n/a
  • pCR Rate: n/a (not applicable in hematologic malignancy context)

Regulatory Milestones

  • Approval Status: FDA accelerated approval granted May 13, 2026
  • Indication: Adults with R/R MCL after ≥2 prior lines of therapy, including a BTK inhibitor
  • Regulatory Pathway: Accelerated approval based on ORR and DoR
  • Regulatory Designations: Priority Review, Breakthrough Therapy Designation, Orphan Drug Designation
  • Regulatory Review: Conducted under Project Orbis

Safety

  • Overall AE Burden: manageable and consistent with BCL-2 inhibitors
  • Grade ≥3 Events: Not fully characterized in early publications
  • Serious Adverse Events: Occurred in 37% of patients
  • Most common serious AE: Pneumonia (10%)
  • Treatment-related deaths: n/a (not reported in FDA summary)
  • Notable toxicity patterns:
    • Cytopenias
    • Tumor lysis syndrome (TLS) risk (requires ramp-up dosing)
    • Serious infections
    • Neutropenia

Key Clinical Implications

✔ Demonstrated meaningful single-agent activity in BTK inhibitor–pretreated MCL, now FDA approved

✔ Oral administration supports outpatient feasibility

✔ Selective BCL-2 targeting may mitigate off-target toxicity

✔ Early efficacy supports regulatory advancement despite non-randomized design

✔ Potential future backbone for combination strategies in MCL

Bottom Line

Sonrotoclax is a newly FDA-approved, next-generation BCL-2 inhibitor for patients with relapsed or refractory mantle cell lymphoma following at least two prior lines of therapy, including a BTK inhibitor. Approval is based on response rate and durability from a single-arm phase I/II study, with confirmatory data pending. Its oral administration, manageable safety profile, and activity in a heavily pretreated population position sonrotoclax as a new targeted option to the evolving treatment landscape in MCL.

Sources: